Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst

22nd December 2017 Uncategorised 0

On a quest to make Revlimid a go-to drug for non-Hodgkin lymphoma, Celgene paired its longtime blockbuster with Rituxan and pitted the two against Rituxan and standard chemo. It was a risky proposition—and it failed.

More: Celgene's Revlimid fails lymphoma trial, and it's more than a data shortfall: analyst
Source: fierce